Skip to main content

Table 5 Effect of each parameter on DCR according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter Univariate Two-variable Multivariablea
Variable Timepoint Value p OR Lower OR Upper OR p OR Lower OR Upper OR p OR Lower OR Upper OR
Platelets Basal  + 10,000      0.077 1.027 0.997 1.058
Δ Ref ≤ 25,000      0.043 1.749 1.019 3.001
White blood cell count Basal  + 100      0.002 1.017 1.006 1.028
Δ Ref ≤ 1920       < 0.001 4.136 1.927 8.878 0.003 3.422 1.528 7.666
Neutrophils Basal  + 100       < 0.001 1.030 1.015 1.044 0.004 1.022 1.007 1.037
Δ Ref ≤ 310      0.021 1.850 1.097 3.120
Lymphocytes Basal  + 100      0.381 0.987 0.957 1.017
Δ Ref ≥ − 300      0.002 2.621 1.444 4.756 0.074 1.804 0.944 3.446
NL ratio Basal  + 1       < 0.001 1.329 1.127 1.568
Δ Ref ≤ 0.86      0.001 2.779 1.503 5.140
PL ratio Basal  + 1      0.086 1.003 1.000 1.006
Δ Ref ≤ 22.85      0.009 2.022 1.191 3.432
Age Basal  + 1 0.879 1.001 0.983 1.020     
Sex Basal Ref F 0.507 0.845 0.514 1.389     
Number of metastatic sites Basal Ref ≥ 3 0.010 0.519 0.316 0.853     
LDH Basal Ref elevated 0.002 0.419 0.243 0.722      0.032 0.528 0.295 0.946
  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. OR (odds ratio) values are expressed in terms of risk of non-response
  4. aAfter stepwise selection